DGAP-News: Apricus Biosciences Announces First Quarter 2011 Financial Results Conference Call
ID: 402841
10.05.2011 15:21
---------------------------------------------------------------------------
Conference Call/Webcast to be Held Friday, May 13, 2011 at 1:00 p.m. ETSAN DIEGO, May 10, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ('Apricus
Bio') (Nasdaq:APRI) announced today that management will hold a conference call
to discuss its first quarter 2011 financial results and ongoing corporate
activities on Friday, May 13, 2011 at 1:00 p.m. ET. The Company will file its
Form 10-Q for the quarter ended March 31, 2011 by the opening of business on
Friday, May 13, 2011.
The call can be accessed in the U.S. by dialing 877-407-8031 and outside of the
U.S. by dialing 201-689-8031 and asking the conference operator for the Apricus
Bio Conference Call. The teleconference replay will be available for one week
by dialing in the U.S. 877-660-6853 and outside of the U.S. by dialing
201-612-7415. Replay passcodes 286 and 371849 are both required for playback.
The conference call will also be Webcast live at
http://www.investorcalendar.com/IC/CEPage.asp?ID=164336. The Webcast replay
will be available for three months.
About Apricus Biosciences, Inc.
Apricus Bio, a San Diego based revenue-generating pharmaceutical company, has
leveraged the flexibility of its clinically-validated NexACT(r) drug delivery
technology to enable multi-route administration of new and improved compounds
across numerous therapeutic classes. Revenues and growth are driven from
out-licensing of this technology for the development and commercialization of
such compounds to pharmaceutical and biotechnology companies worldwide. In
addition, the Company is seeking to monetize its existing product pipeline,
including its first product, Vitaros(r), approved in Canada for the treatment of
erectile dysfunction, which is currently expected to be available on the
Canadian market in 2011, as well as compounds in development from pre-clinical
through Phase III, currently focused on sexual dysfunction, oncology,
dermatology, autoimmune, pain, anti-infectives, diabetes and cosmeceuticals
among others.
For further information on Apricus Bio, visit http://www.apricusbio.com and for
information on its subsidiaries please visit www.nexmedusa.com or
www.bio-quant.com. You can also find out more about the company by visiting
http://twitter.com/apricusbio http://facebook.com/apricusbio.
Apricus Bio's Forward-Looking Statement Safe Harbor
Statements under the Private Securities Litigation Reform Act, as amended: with
the exception of the historical information contained in this release, the
matters described herein contain forward-looking statements that involve risks
and uncertainties that may individually or mutually impact the matters herein
described for a variety of reasons that are outside the control of the Company,
including, but not limited to, its ability to enter into license agreements
with potential pharmaceutical partners and obtain upfront and milestone
payments as well as royalties and to achieve other of its financial goals.
Readers are cautioned not to place undue reliance on these forward-looking
statements as actual results could differ materially from the forward-looking
statements contained herein. Readers are urged to read the risk factors set
forth in the Company's most recent annual report on Form 10-K, subsequent
quarterly reports filed onForm 10-Q and other filings made with the SEC.
Copies of these reports are available from the SEC's website or without charge
from the Company.
CONTACT: Apricus Biosciences, Inc.
Edward Cox, V.P.
Investor Relations&Corporate Development
Apricus Bio, Inc.
(858) 848-4249
ecox@apricusbio.com
Apricus Bio Investor Relations
Paula Schwartz
Rx Communications Group, LLC
(917) 322-2216
pschwartz@rxir.com
News Source: NASDAQ OMX
10.05.2011 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Apricus Biosciences, Inc.
United States
Phone:
Fax:
E-mail:
Internet:
ISIN: US9901429525
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------Unternehmensinformation / Kurzprofil:
Datum: 10.05.2011 - 15:21 Uhr
Sprache: Deutsch
News-ID 402841
Anzahl Zeichen: 5337
Kontakt-Informationen:
Kategorie:
Wirtschaft (allg.)
Diese Pressemitteilung wurde bisher 231 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Apricus Biosciences Announces First Quarter 2011 Financial Results Conference Call"
steht unter der journalistisch-redaktionellen Verantwortung von
Apricus Biosciences, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
